+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

United States Proton Therapy Market, Size, Forecast 2022-2027, Industry Trends, Impact of COVID-19, Growth, Opportunity Company Analysis

  • ID: 5521691
  • Report
  • January 2022
  • Region: United States
  • 200 Pages
  • Renub Research

FEATURED COMPANIES

  • Elekta
  • IBA Proton Therapy
  • Varian Medical Systems
The United States Proton Therapy Market is expected to reach US$ 1.8 Billion by 2027. Proton therapy is an excellent treatment alternative for numerous patients, especially those with tumours close to vital organs. Besides, for children, those most vulnerable and susceptive to the damage of conventional radiation therapy, proton therapy offers less radiation exposure while demoting side effects. In addition, proton therapy is a high-tech option for X-ray radiation. With online image guidance, a scanning beam of proton radiation advises greater precision to destroy carcinogenic cells, sparing adjacent healthy tissue with more infrequent side effects.



COVID-19 Impact on United States Proton Therapy Industry:


Despite the outbreak of COVID-19 worldwide, the proton therapy market has increased at a constant speed. It was only stopped for a brief period in the initial months of the pandemic outbreak but later resumed to take care of the cancer patients and radiation therapies patients in the United States; many procedures have been finalized to help the patients with therapies. Such as, many implementations and algorithms have been carried out to safeguard the radiation patients from COVID-19.

United States Proton Therapy Market will grow with a CAGR of 8.5% during the period 2021-2027


The rise of the proton therapy industry in the United States is mainly driven by rising healthcare expenditure, expanding preference for advanced therapies by healthcare practitioners, increasing confirmation and increasing cancer pervasiveness. Another outstanding growth driver is the faster uptake and access along with premium pricing. As per the analysis, United States Proton Therapy Market Size was US$ 1.1 Billion post-pandemic recoveries in 2021.

Cancer Types - Market Segmentation:


Based on Cancer Types, the proton therapy market of the United States is further segmented into Central Nervous System Tumors, Intraocular Melanomas Cancer, Pituitary Neoplasms Cancer, Base of Skull / Axial Skeleton Cancer, Head and Neck Cancer, Lung Cancer, Retroperitoneal Sarcoma Cancer, Pediatric Cancer (Up to Age 18), Gastrointestinal Tract Cancer, Urinary Tract Cancer, Female Pelvic Organs Cancer, Prostate Cancer, and Breast Cancer.

Besides, proton therapy applications are more inclined towards Gastrointestinal Tract Cancer and lung cancer due to references by healthcare specialists. Moreover, proton therapy is also recognized to be comparatively safer in the case of paediatric patients who have cancer. These applications are anticipated to drive the revenue for the proton therapy industry over the forecast period.

Competitive Landscape:


Companies in the United States Proton Therapy Market are trying to create their mark by adopting new technologies at an accelerated rate. The company has also tried to enrich their product catalogues through product developments. Also, companies have acquired small companies to resolve the potential resource gap that prevailed in their technologies and products. The major players of the United States Proton Therapy Market studied in the report are IBA Proton Therapy, Varian Medical Systems, and Elekta.

This latest report “Proton Therapy Patients Number & Market, Global Forecast By Cancer Types (Central Nervous System Tumors, Intraocular Melanomas Cancer, Pituitary Neoplasms Cancer, Base of Skull / Axial Skeleton Cancer, Head and Neck Cancer, Lung Cancer, Retroperitoneal Sarcoma Cancer, Pediatric Cancer (Up to Age 18), Gastrointestinal Tract Cancer, Urinary Tract Cancer, Female Pelvic Organs Cancer, Prostate Cancer, Breast Cancer and Others), Company (IBA Proton Therapy, Varian Medical Systems, Elekta)” provides a detailed analysis of United States Proton Therapy Industry.

Cancer Types - United States Proton Therapy Market has been covered from 14 viewpoints:


1. Central Nervous System Tumors
2. Intraocular Melanomas Cancer
3. Pituitary Neoplasms Cancer
4. Base of Skull / Axial Skeleton Cancer
5. Head and Neck Cancer
6. Lung Cancer
7. Retroperitoneal Sarcoma Cancer
8. Pediatric Cancer Cases (Up to Age 18)
9. Gastrointestinal Tract Cancer
10. Urinary Tract Cancer
11. By Female Pelvic Organs Cancer
12. Prostate Cancer
13. Breast Cancer
14. Other Cancer

Cancer Types - Patients Number in United States Proton Therapy Market has been covered from 14 viewpoints:


1. Central Nervous System Tumors
2. Intraocular Melanomas Cancer
3. Pituitary Neoplasms Cancer
4. Base of Skull / Axial Skeleton Cancer
5. Head and Neck Cancer
6. Lung Cancer
7. Retroperitoneal Sarcoma Cancer
8. Pediatric Cancer (Up to Age 18)
9. Gastrointestinal Tract Cancer
10. Urinary Tract Cancer
11. Female Pelvic Organs Cancer
12. Prostate Cancer
13. Breast Cancer
14. Other Cancer

All companies have been covered from 3 viewpoints:

  • Overview
  • Recent Developments
  • Sales Analysis

Companies Covered:


1. IBA Proton Therapy
2. Varian Medical Systems
3. Elekta
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Elekta
  • IBA Proton Therapy
  • Varian Medical Systems
1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Market (Actual & Potential) - United States Proton Therapy Market
5.1 Actual Proton Therapy Market
5.2 Potential Proton Therapy Market

6. Number of Patients - United States Proton Therapy
6.1 Actual Numbers
6.2 Potential Numbers

7. Cancer Types - United States Proton Therapy Market
7.1 Central Nervous System Tumors
7.2 Intraocular Melanomas Cancer
7.3 Pituitary Neoplasms Cancer
7.4 Base of Skull / Axial Skeleton Cancer
7.5 Head and Neck Cancer
7.6 Lung Cancer
7.7 Retroperitoneal Sarcoma Cancer
7.8 Pediatric Cancer Cases (Up to Age 18)
7.9 Gastrointestinal Tract Cancer
7.10 Urinary Tract Cancer
7.11 By Female Pelvic Organs Cancer
7.12 Prostate Cancer
7.13 Breast Cancer
7.14 Other Cancer

8. Cancer Types - United States Proton Therapy Patients Numbers
8.1 Central Nervous System Tumors
8.2 Intraocular Melanomas Cancer
8.3 Pituitary Neoplasms Cancer
8.4 Base of Skull / Axial Skeleton Cancer
8.5 Head and Neck Cancer
8.6 Lung Cancer
8.7 Retroperitoneal Sarcoma Cancer
8.8 Pediatric Cancer (Up to Age 18)
8.9 Gastrointestinal Tract Cancer
8.10 Urinary Tract Cancer
8.11 Female Pelvic Organs Cancer
8.12 Prostate Cancer
8.13 Breast Cancer
8.14 Other Cancer

9. United States - List of Proton Therapy Centers
9.1 Operating Proton Therapy Centers
9.2 Under-Construction Therapy Centers
9.3 Planning Proton Therapy Centers

10. Proton Therapy - Reimbursement Policies
10.1 Proton Therapy Reimbursement Policies for Patients
10.2 Proton Therapy Reimbursement for Institutions, Stakeholders and Manufacturers

11. Components of a Standard Proton Therapy Center
11.1 Proton Accelerator
11.1.1 Synchrotrons (example: LLUMC at Loma Linda)
11.1.2 Cyclotrons (example: MGH Boston)
11.1.3 Synchrocyclotrons (examples: Orsay, Uppsala)
11.1.4 Linacs (Rome)
11.1.5 H-minus Synchrotrons
11.1.6 Separated Sector Cyclotrons
11.1.7 Super-conducting Cyclotrons
11.1.8 Fast Cycling Synchrotron
11.2 Beam Transport System
11.3 Beam Delivery System
11.3.1 The Passive Scattering Technique
11.3.2 Beam Scanning
11.4 Nozzle
11.4.1 Single Scattering
11.4.2 Double Scattering
11.4.3 Uniform Scanning Nozzle
11.4.4 Pencil Scanning Nozzle
11.5 Treatment Planning System
11.6 Image Viewers
11.7 Patient Positioning System (PPS)
11.8 Human Resource

12. Porters Five Forces
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13. Company Analysis
13.1 IBA Proton Therapy
13.1.1 Overview
13.1.2 Recent Developments
13.1.3 Sales Analysis
13.2 Varian Medical Systems
13.2.1 Overview
13.2.2 Recent Developments
13.2.3 Sales Analysis
13.3 Elekta
13.3.1 Overview
13.3.2 Recent Developments
13.3.3 Sales Analysis

List of Figures:
Figure-01: United States - Actual Proton Therapy Market (Million US$), 2016 - 2021
Figure-02: United States - Forecast for Actual Proton Therapy Market (Million US$), 2022 - 2027
Figure-03: United States - Potential Proton Therapy Market (Million US$), 2016 - 2021
Figure-04: United States - Forecast for Potential Proton Therapy Market (Million US$), 2022 - 2027
Figure-05: United States - Actual Numbers Patients Volume (Number), 2016 - 2021
Figure-06: United States - Forecast for Actual Numbers Patients Volume (Number), 2022 - 2027
Figure-07: United States - Potential Numbers Patients Volume (Number), 2016 - 2021
Figure-08: United States - Forecast for Potential Numbers Patients Volume (Number), 2022 - 2027
Figure-09: Central Nervous System Tumors Patients Volume (Number), 2016 - 2021
Figure-10: Forecast for - Central Nervous System Tumors Patients Volume (Number), 2022 - 2027
Figure-11: Intraocular Melanomas Cancer Patients Volume (Number), 2016 - 2021
Figure-12: Forecast for - Intraocular Melanomas Cancer Patients Volume (Number), 2022 - 2027
Figure-13: Pituitary Neoplasms Cancer Patients Volume (Number), 2016 - 2021
Figure-14: Forecast for - Pituitary Neoplasms Cancer Patients Volume (Number), 2022 - 2027
Figure-15: Base of Skull / Axial Skeleton Cancer Patients Volume (Number), 2016 - 2021
Figure-16: Forecast for - Base of Skull / Axial Skeleton Cancer Patients Volume (Number), 2022 - 2027
Figure-17: Head and Neck Cancer Patients Volume (Number), 2016 - 2021
Figure-18: Forecast for - Head and Neck Cancer Patients Volume (Number), 2022 - 2027
Figure-19: Lung Cancer Patients Volume (Number), 2016 - 2021
Figure-20: Forecast for - Lung Cancer Patients Volume (Number), 2022 - 2027
Figure-21: Retroperitoneal Sarcoma Cancer Patients Volume (Number), 2016 - 2021
Figure-22: Forecast for - Retroperitoneal Sarcoma Cancer Patients Volume (Number), 2022 - 2027
Figure-23: Pediatric Cancer Cases (Up to Age 18) Patients Volume (Number), 2016 - 2021
Figure-24: Forecast for - Pediatric Cancer Cases (Up to Age 18) Patients Volume (Number), 2022 - 2027
Figure-25: Gastrointestinal Tract Cancer Patients Volume (Number), 2016 - 2021
Figure-26: Forecast for - Gastrointestinal Tract Cancer Patients Volume (Number), 2022 - 2027
Figure-27: Urinary Tract Cancer Patients Volume (Number), 2016 - 2021
Figure-28: Forecast for - Urinary Tract Cancer Patients Volume (Number), 2022 - 2027
Figure-29: By Female Pelvic Organs Cancer Patients Volume (Number), 2016 - 2021
Figure-30: Forecast for - By Female Pelvic Organs Cancer Patients Volume (Number), 2022 - 2027
Figure-31: Prostate Cancer Patients Volume (Number), 2016 - 2021
Figure-32: Forecast for - Prostate Cancer Patients Volume (Number), 2022 - 2027
Figure-33: Breast Cancer Patients Volume (Number), 2016 - 2021
Figure-34: Forecast for - Breast Cancer Patients Volume (Number), 2022 - 2027
Figure-35: Other Cancer Patients Volume (Number), 2016 - 2021
Figure-36: Forecast for - Other Cancer Patients Volume (Number), 2022 - 2027
Figure-37: Central Nervous System Tumors Market (Million US$), 2016 - 2021
Figure-38: Forecast for - Central Nervous System Tumors Market (Million US$), 2022 - 2027
Figure-39: Intraocular Melanomas Cancer Market (Million US$), 2016 - 2021
Figure-40: Forecast for - Intraocular Melanomas Cancer Market (Million US$), 2022 - 2027
Figure-41: Pituitary Neoplasms Cancer Market (Million US$), 2016 - 2021
Figure-42: Forecast for - Pituitary Neoplasms Cancer Market (Million US$), 2022 - 2027
Figure-43: Base of Skull / Axial Skeleton Cancer Market (Million US$), 2016 - 2021
Figure-44: Forecast for - Base of Skull / Axial Skeleton Cancer Market (Million US$), 2022 - 2027
Figure-45: Head and Neck Cancer Market (Million US$), 2016 - 2021
Figure-46: Forecast for - Head and Neck Cancer Market (Million US$), 2022 - 2027
Figure-47: Lung Cancer Market (Million US$), 2016 - 2021
Figure-48: Forecast for - Lung Cancer Market (Million US$), 2022 - 2027
Figure-49: Retroperitoneal Sarcoma Cancer Market (Million US$), 2016 - 2021
Figure-50: Forecast for - Retroperitoneal Sarcoma Cancer Market (Million US$), 2022 - 2027
Figure-51: Pediatric Cancer (Up to Age 18) Market (Million US$), 2016 - 2021
Figure-52: Forecast for - Pediatric Cancer (Up to Age 18) Market (Million US$), 2022 - 2027
Figure-53: Gastrointestinal Tract Cancer Market (Million US$), 2016 - 2021
Figure-54: Forecast for - Gastrointestinal Tract Cancer Market (Million US$), 2022 - 2027
Figure-55: Urinary Tract Cancer Market (Million US$), 2016 - 2021
Figure-56: Forecast for - Urinary Tract Cancer Market (Million US$), 2022 - 2027
Figure-57: Female Pelvic Organs Cancer Market (Million US$), 2016 - 2021
Figure-58: Forecast for - Female Pelvic Organs Cancer Market (Million US$), 2022 - 2027
Figure-59: Prostate Cancer Market (Million US$), 2016 - 2021
Figure-60: Forecast for - Prostate Cancer Market (Million US$), 2022 - 2027
Figure-61: Breast Cancer Market (Million US$), 2016 - 2021
Figure-62: Forecast for - Breast Cancer Market (Million US$), 2022 - 2027
Figure-63: Other Cancer Market (Million US$), 2016 - 2021
Figure-64: Forecast for - Other Cancer Market (Million US$), 2022 - 2027
Figure-65: IBA Proton Therapy - Global Revenue (Million US$), 2016 - 2021
Figure-66: IBA Proton Therapy - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure-67: Varian Medical Systems - Global Revenue (Million US$), 2016 - 2021
Figure-68: Varian Medical Systems - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure-69: Elekta - Global Revenue (Million US$), 2016 - 2021
Figure-70: Elekta - Forecast for Global Revenue (Million US$), 2022 - 2027

List of Tables:
Table-01: Operating Proton Therapy Centers
Table-02: Under-Construction Therapy Centers
Table-03: Planning Proton Therapy Centers
Note: Product cover images may vary from those shown
  • IBA Proton Therapy
  • Varian Medical Systems
  • Elekta
Note: Product cover images may vary from those shown

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...